Inicio・Lista de Acciones・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Cerrado

SectorSanidad

19.11 1.16

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

18.8

Máximo

19.34

Métricas clave
By Trading Economics
Ingresos	-24M -54M
Ventas	-2.5M 305M
BPA	-0.15
Margen de beneficios	-17.851
Empleados	3,100
EBITDA	-24M -32M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+175.38% upside

Dividendos
By Acuity
Próximas Ganancias	11 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1B 3.7B
Apertura anterior	17.95
Cierre anterior	19.11

Noticias sobre sentimiento de mercado

By Acuity

100%

320 / 340 Clasificación en Healthcare

Legend Biotech Corp ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 jul 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 jul 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 jul 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 jul 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 jul 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 jul 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 jul 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 jul 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 jul 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Comparación entre iguales

Cambio de precio

Legend Biotech Corp ADR previsión

Precio Objetivo

By TipRanks

175.38% repunte

Estimación a 12 Meses

Media 52.35 USD 175.38%

Máximo 80 USD

Mínimo 28 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Legend Biotech Corp ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Legend Biotech Corp ADR Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.